Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Trastornos del Movimiento

3520 ARTÍCULOS , VIENDO DEL 1756 AL 1770

Dihydropyridine calcium channel blockers and the progression of parkinsonism

Marras C, Gruneir A, Rochon P, Wang X, Anderson G, Brotchie J, Bell CM, Fox S, Austin PC.

Ann Neurol. 2012 Mar;71(3):362-9. doi: 10.1002/ana.22616.

Meta-analysis of Parkinson's disease: identification of a novel locus, RIT2

Pankratz N, Beecham GW, DeStefano AL, Dawson TM, Doheny KF, Factor SA, Hamza TH, Hung AY, Hyman BT, Ivinson AJ, Krainc D, Latourelle JC, Clark LN, Marder K, Martin ER, Mayeux R, Ross OA, Scherzer CR, Simon DK, Tanner C, Vance JM, Wszolek ZK, Zabetian CP, Myers RH, Payami H, Scott WK, Foroud T; PD GWAS Consortium.

Ann Neurol. 2012 Mar;71(3):370-84. doi: 10.1002/ana.22687.

The neuropathology of genetic Parkinson's disease

Poulopoulos M, Levy OA, Alcalay RN.

Mov Disord. 2012 Jun;27(7):831-42. doi: 10.1002/mds.24962. Epub 2012 Mar 26.

Fixing the broken system of genetic locus symbols: Parkinson disease and dystonia as examples

Marras C, Lohmann K, Lang A, Klein C.

Neurology. 2012 Mar 27;78(13):1016-24. doi: 10.1212/WNL.0b013e31824d58ab.

Use of the Gait Deviation index for the evaluation of patients with Parkinson's disease

Galli M, Cimolin V, De Pandis MF, Schwartz MH, Albertini G.

J Mot Behav. 2012;44(3):161-7. doi: 10.1080/00222895.2012.664180. Epub 2012 Mar 28.

Great promise of tissue-resident adult stem/progenitor cells in transplantation and cancer therapies

Mimeault M, Batra SK.

Adv Exp Med Biol. 2012;741:171-86. doi: 10.1007/978-1-4614-2098-9_12.

Are you or aren't you? Challenges associated with physiologically identifying dopamine neurons

Ungless MA, Grace AA.

Trends Neurosci. 2012 Jul;35(7):422-30. doi: 10.1016/j.tins.2012.02.003. Epub 2012 Mar 28.

Activity enhances dopaminergic long-duration response in Parkinson disease

Kang UJ, Auinger P; Parkinson Study Group ELLDOPA Investigators.

Neurology. 2012 Apr 10;78(15):1146-9. doi: 10.1212/WNL.0b013e31824f8056. Epub 2012 Mar 28.

The molecular basis of dopaminergic brain imaging in Parkinson's disease

Seibyl J, Russell D, Jennings D, Marek K.

Q J Nucl Med Mol Imaging. 2012 Feb;56(1):4-16.

The role of molecular imaging in the differential diagnosis of parkinsonism

Booij J, Teune LK, Verberne HJ.

Q J Nucl Med Mol Imaging. 2012 Feb;56(1):17-26.

Identification of biomarkers in Lewy-body disorders

Warr L, Walker Z.

Q J Nucl Med Mol Imaging. 2012 Feb;56(1):39-54.

Cognitive impairment in degenerative parkinsonisms: role of radionuclide brain imaging

Arnaldi D, Morbelli S, Morrone E, Campus C, Nobili F.

Q J Nucl Med Mol Imaging. 2012 Feb;56(1):55-67.

Community-based exercise and wellness program for people diagnosed with Parkinson disease: experiences from a 10-month trial

Steffen T, Petersen C, Dvorak L.

J Geriatr Phys Ther. 2012 Oct-Dec;35(4):173-80. doi: 10.1519/JPT.0b013e31824a1c9d.

Electrochemical determination of glutathione: a review

Harfield JC, Batchelor-McAuley C, Compton RG.

Analyst. 2012 May 21;137(10):2285-96. doi: 10.1039/c2an35090d. Epub 2012 Mar 29.

5-3’-[(18)F]Fluoropropyl-3-[2-((S)-pyrrolidinyl)methoxy]pyridine

Leung K.

2006 Sep 18 [updated 2012 Apr 3]. In: Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2004–2013.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias